Obesity-related glomerulopathy — driven by glomerulomegaly, focal segmental glomerulosclerosis, and hyperfiltration — accelerates CKD through insulin resistance, hypertension, and systemic inflammation. Across observational studies and meta-analyses, bariatric surgery consistently reduces albuminuria, slows eGFR decline, and lowers incident CKD and kidney failure risk. Patients with CKD stages 3–4 frequently show stabilization or functional improvement postoperatively. In end-stage renal disease, sleeve gastrectomy (SG) safely reduces BMI to expand kidney transplant eligibility. Roux-en-Y gastric bypass (RYGB) delivers the strongest metabolic benefits but meaningfully elevates hyperoxaluria and nephrolithiasis risk — a clinically underappreciated trade-off.
This review consolidates a growing but still observational evidence base. The renal benefits of bariatric surgery align with known mechanisms: blood pressure normalization, glycemic improvement, and inflammation reduction each independently reduce glomerular stress. The RYGB-hyperoxaluria link is mechanistically understood — enteric fat malabsorption increases colonic oxalate absorption — making it actionable: patients with pre-existing stone disease or reduced GFR should preferentially receive SG. What remains genuinely weak is the evidence quality. Kidney-specific endpoints are rarely primary outcomes in bariatric trials, follow-up beyond five years is sparse, and CKD populations are systematically underrepresented. The call to integrate GLP-1 receptor agonists and SGLT2 inhibitors is timely; both drug classes independently protect renal function and could amplify surgical gains. This analysis is confirmatory rather than paradigm-shifting, but its clinical utility is real: procedure selection in obese CKD patients should now be explicitly informed by renal phenotype.